Personalis extends Tempus agreement to add colorectal cancer indication

Personalis, Inc. (PSNL) has significantly expanded its market reach and demonstrated strong operational performance, driven by an amended agreement with Tempus AI to include colorectal cancer as a new indication for its NeXT Personal ultra-sensitive minimal residual disease (MRD) test, extending exclusivity through 2028. This strategic expansion complements robust Q1 2025 financial results, where the company surpassed revenue and EPS expectations with NeXT Personal test growth of 52%, alongside new clinical data showing the test's ability to predict cervical cancer progression earlier. These developments, coupled with H.C. Wainwright raising its price target, underscore Personalis' advancements in precision oncology and its growth trajectory in the MRD testing market.

Analysis

Personalis, Inc. (PSNL) has demonstrated significant operational and strategic momentum, underpinned by a newly amended agreement with Tempus AI. This amendment extends their partnership to 2029 and critically expands the commercialization of the NeXT Personal minimal residual disease (MRD) test to include colorectal cancer, adding to existing indications for breast and lung cancer. The deal structure is notable for its mutual exclusivity through 2028, which secures a key commercial channel for Personalis while limiting near-term competition for Tempus in these specific, high-value oncology markets. This strategic development is reinforced by strong first-quarter 2025 financial results, where Personalis reported revenue of $20.6 million, substantially beating analyst expectations of $17.5 million, and an EPS of -$0.18, which was better than the anticipated -$0.25. This performance was directly fueled by a 52% quarter-over-quarter increase in its NeXT Personal molecular test volumes. Further bolstering the company's outlook, H.C. Wainwright raised its price target to $9.00 from $8.00, and recent clinical data from the CALLA study indicated the NeXT Personal test can predict cervical cancer progression up to 16 months earlier than imaging, highlighting the platform's technological strength and potential for future indication expansion.

Key Decisions for Investors

• Investors should view the combination of a significant Q1 earnings beat, the expanded and exclusive Tempus commercial agreement, and positive analyst revisions as strong validation of the company's growth strategy in the competitive MRD market.
• Monitor the company's progress on securing broader reimbursement coverage for its NeXT Personal platform, as this remains a critical catalyst for driving long-term revenue growth and achieving profitability.
• While the deepened partnership with Tempus de-risks commercial execution, investors should also consider the concentration risk, as Personalis's success in its core cancer indications is now intrinsically linked to Tempus's performance through 2028.